How R&D Tax Credits Can Boost Company Valuations

Yes, they can. R&D tax credits can enhance company valuation when the benefit is sustainable, correctly accounted for and defensible in due diligence. In many cases, businesses across the UK treat R&D tax credits as a short-term cash inflow rather than a strategic asset. When these R&D tax credits are embedded into long-term business planning, they can strengthen EBITDA, reduce risk and support predictable cash flows.

Used consistently, R&D tax credits play a meaningful role in increasing enterprise value, particularly for those running innovation-led businesses that are preparing for investment or exit strategies. So, you may be left with one important question: how do R&D tax credits increase company valuations? In this article, we are going to be explaining more about what buyers look for in due diligence and how to position your R&D claim to maximise business value at the exit stage.

Why are R&D tax credits viewed as value-enhancing by buyers?

While R&D tax credits were initially introduced to reward UK companies for overcoming scientific or technological uncertainties, there is a great range of benefits you can unlock. A consistent history of claiming R&D credits demonstrates your business is actively developing innovative products, technology or processes that can be evidenced as qualifying R&D for HMRC purposes, and you could benefit from investors and acquirers in the future. This is exactly what makes R&D value-enhancing and attractive to buyers.

Whether you’re developing an innovative project that qualifies for R&D, or improving an existing project. Ensuring that business expenditure is correctly documented as qualifying R&D costs can contribute significantly to a higher business value.

How does R&D tax credit strengthen business EBITDA?

Adjusted EBITDA can be significantly impacted by R&D tax credits when claims are prepared and accounted for correctly. The R&D tax credits EBITDA impact is particularly relevant to consider under the Merged Scheme as this is where the credit is recognised above the line as other operating income.

Unlike revenue growth, which often requires additional sales or expansion within the market, R&D tax credits improve profitability by reducing the net cost of innovation. This can strengthen operating margins without increasing complexities. EBITDA and margin quality are central to valuation methods, so this uplift can translate directly into enterprise value when the income is classed as sustainable.

How does a well-prepared R&D claim support a smoother due diligence process?

Well-prepared R&D claims can significantly reduce delays during the due diligence process by avoiding technical and legal uncertainties. A well-supported R&D report acts as a formal record of innovation and this proves that your innovative process is genuine, well-documented and owned by your business. It also reassures buyers that your intellectual property is not easily replicable. 

From an investor’s perspective, project risks can delay decisions and potentially raise concerns. By completing clear R&D documentation, it reduces the risk of any uncertainty during the process of due diligence and reduces burden on legal and technical advisers. By presenting reports to advisory experts, it helps keep the process simple and quick with fewer objections. 

Can unused R&D losses be transferred as part of a company sale?

Sometimes yes, however buyers will assess usability rather than assume the headline value.  Early-stage projects or businesses are often pre-profit but may have accumulated significant losses through sustained R&D investments. These losses may not benefit immediately, however, in a share sale, R&D-enhanced losses could potentially be carried forward within the same company. R&D-enhanced losses can also be potentially offset against future profits; this would be subject to change-of-ownership and continuity regulations under UK tax law. 

How do the SME and Merged R&D Schemes differ in valuation terms?

From a valuation perspective, the Merged Scheme is often more advantageous, as R&D tax credits are more commonly treated as operating income, this can positively impact EBITDA-based valuations. In contrast, the former SME scheme typically delivered value through a reduction in corporation tax, which tends to have a more limited impact on headline valuation metrics.

These differences are particularly relevant in business exit tax planning in the UK, as the way R&D credits are recognised can directly influence operating profit and EBITDA during an investment or sale process.

Under the SME scheme, R&D tax credits were often received as a reduction in corporation tax or as a repayable credit. While this improved cash flow, it did not always enhance operating profit or EBITDA.

Under the modern Merged Scheme, the credit can be recognised above the line as other operating income, meaning it may increase EBITDA, subject to accounting policy. Understanding the accounting treatment for R&D tax credits is vital, as the way credit is classed, it can directly influence operating profits and EBITDA that is reported.

Although the cash benefit may be slightly lower than under the SME scheme, the improved visibility and quality of earnings is often more attractive to investors, acquirers, and lenders.

When is the best time to submit an R&D claim before a company sale?

As a wider part of business succession planning, it is ideal that eligible R&D claims should be completed 6 months prior to the beginning of a sale process. Having the cash received and the completed supporting documentation helps strengthen finances and presents a clear picture of your business’ position to buyers. 

However, if you submit a last-minute and unorganised claim immediately ahead of a transaction, it could raise questions and concerns regarding the sustainability and compliance of your business. This could potentially slow the sale process which will create unnecessary uncertainty for buyers.

FAQs:

Do R&D credits count towards EBITDA?

Yes, in many cases. When a business is claiming under the new Merged Scheme, R&D tax credits are typically recognised above the line as taxable income. This may result in an increase of EBITDA, subject to accounting policies and how you present your claim.

Does having an R&D claim make my company easier to sell?

In many cases, yes. Having a history of R&D claims shows that your technology has qualified for government incentives and your financial records are well documented, therefore if you were to sell your company you would be at an advantage having an R&D claim.

Are R&D tax credits treated as revenue or a tax reduction?

This depends on the scheme, so let us explain. If your accounting period began on or after 1st April 2024, your R&D claim will have fallen under the new Merged Scheme. The credit is often classified as ‘above the line’ in your profit and loss account, therefore it will increase your income before tax.

Is the R&D report useful during buyer negotiations?

Yes. A Research and Development, R&D, report is prepared in line with HMRC’s guidelines and supported by technical and financial evidence. It demonstrates the existence and nature of your business’ technical innovation which will strengthen your negotiating position for the company’s sale price. 

If you are considering how R&D tax credits can be aligned with long-term valuation and exit planning, please visit our website or contact a member of our team where you can find out additional information.